Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Mark Foundation for Cancer Research ×

Mark Foundation for Cancer Research

This funder is selected. Its supporting articles are shown below.

Mark Foundation for Cancer Research1

Articles mentioning Mark Foundation for Cancer Research

1 articles · page 1 of 1

599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma

jitc · abstract · 2025-11-04 · 1 matching annotations

77.4%

Mark Foundation for Cancer Research EMD Serono tuvusertib ceralasertib durvalumab avelumab AZD6738

…ease. EDDOP Leadership Award-P30 Administrative Supplement, the Mark Foundation for Cancer Research, the Kelsey Dickson Team Science Courage Research Team Award, a…

Browse funders

Mark Foundation for Cancer Research

Articles mentioning Mark Foundation for Cancer Research

599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma